Cipla announces JV with Kemwell Biopharma and Manipal Group for cell therapy development
Cipla (EU) Limited, UK, a wholly-owned subsidiary of Cipla Limited, has entered into a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & ... Read More
Cipla expands digital healthcare reach with further investment in GoApptiv
Cipla Limited, a leading pharmaceutical company, has announced its decision to further invest approximately INR 42 crore in digital tech company GoApptiv Private Limited. This ... Read More
Cipla’s InvaGen Pharmaceuticals recalls Vigabatrin over seal integrity concerns
InvaGen Pharmaceuticals Inc., a wholly-owned subsidiary of Cipla Limited, has announced a voluntary recall of one lot of Vigabatrin for Oral Solution, USP 500mg, to ... Read More
Cipla to acquire Actor Pharma to dominate South African OTC market
In a strategic move that amplifies its commitment to the Over-The-Counter (OTC) business, Cipla South Africa, a 100% owned subsidiary of Cipla Limited (BSE: 500087; ... Read More
Cipla launches Cippoint point-of-care testing device in India
Indian pharma company Cipla Limited has launched a point-of-care testing device called Cippoint in India for infectious diseases, non-communicable diseases, and other health conditions. The ... Read More
Cipla receives six observations from FDA for Goa manufacturing facility
Cipla Ltd said that the US Food and Drug Administration (FDA) has concluded an inspection of the company’s manufacturing facility in Goa and has made ... Read More
Cipla takes stake in renewable energy SPV Clean Max Auriga Power
Cipla Limited said that it has acquired a stake of up to 33% in Clean Max Auriga Power LLP, a special purpose vehicle (SPV) focused ... Read More
Cipla Limited amends Pulmazole agreement with Pulmatrix
Cipla Limited said that its fully-owned step-down subsidiary — Cipla Technologies (CipTec) has completed an amendment to a previously signed agreement with US-based Pulmatrix for ... Read More
Cipla Q2 FY22 profit after tax increases 7% to Rs 665cr
Cipla Limited has reported a profit after tax (PAT) of INR 711 crores for the second quarter of the fiscal year 2022 (Q2 FY22), a ... Read More
Cipla signs licensing deal with Lilly to sell two diabetes drugs in India
Cipla has signed a licensing deal with the Indian subsidiary of US pharma giant Eli Lilly and Company (Lilly) pertaining to the latter’s diabetes treatments ... Read More